Basilea News http://www.basilea.com/ Basilea News en Fri, 19 Sep 2014 01:44:28 +0200 Fri, 19 Sep 2014 01:44:28 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea's partner Astellas receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis]]> http://www.basilea.com/News-and-Media/Basileas-partner-Astellas-receives-notification-from-U-S-FDA-of-acceptance-of-filing-of-isavuconazole-NDA-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis/90aab6a2-6fc6-039f-ce48-69a7c30ba6a1 Sat, 06 Sep 2014 14:15:00 +0200 http://www.basilea.com/News-and-Media/Basileas-partner-Astellas-receives-notification-from-U-S-FDA-of-acceptance-of-filing-of-isavuconazole-NDA-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis/90aab6a2-6fc6-039f-ce48-69a7c30ba6a1 <![CDATA[Extensive data presented on Basilea's anti-infectives isavuconazole, ceftobiprole and BAL30072 at ICAAC ]]> http://www.basilea.com/News-and-Media/Extensive-data-presented-on-Basileas-anti-infectives-isavuconazole-ceftobiprole-and-BAL30072-at-ICAAC/fd484025-813a-7abf-e099-c851576126b3 Fri, 05 Sep 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Extensive-data-presented-on-Basileas-anti-infectives-isavuconazole-ceftobiprole-and-BAL30072-at-ICAAC/fd484025-813a-7abf-e099-c851576126b3 <![CDATA[European Medicines Agency accepts Basilea's isavuconazole Marketing Authorization Application for review]]> http://www.basilea.com/News-and-Media/European-Medicines-Agency-accepts-Basileas-isavuconazole-Marketing-Authorization-Application-for-review/261f60fb-2ee1-7218-fe95-fbc152ffcd4a Thu, 21 Aug 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/European-Medicines-Agency-accepts-Basileas-isavuconazole-Marketing-Authorization-Application-for-review/261f60fb-2ee1-7218-fe95-fbc152ffcd4a <![CDATA[Basilea appoints Chief Commercial Officer]]> http://www.basilea.com/News-and-Media/Basilea-appoints-Chief-Commercial-Officer/8bd9f423-2cba-b3aa-a8e0-e34075f40d3a Mon, 18 Aug 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-appoints-Chief-Commercial-Officer/8bd9f423-2cba-b3aa-a8e0-e34075f40d3a <![CDATA[Basilea reports 2014 half-year financials - ceftobiprole launch in Germany planned for second half of 2014]]> http://www.basilea.com/News-and-Media/Basilea-reports-2014-half-year-financials-ceftobiprole-launch-in-Germany-planned-for-second-half-of-2014/6bef004a-03b7-6db4-bccd-7c8db23eb16c
  • Solid operational and financial performance
  • Basilea submitted isavuconazole European MAA and Astellas Pharma Inc. submitted U.S. NDA
  • Full rights to isavuconazole obtained outside U.S. and Canada
  • Cash and short-term investments of CHF 246 million
  • ]]>
    Thu, 14 Aug 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-2014-half-year-financials-ceftobiprole-launch-in-Germany-planned-for-second-half-of-2014/6bef004a-03b7-6db4-bccd-7c8db23eb16c
    <![CDATA[Basilea to launch Zevtera®/Mabelio® (ceftobiprole medocaril) in Europe through a commercial services provider]]> http://www.basilea.com/News-and-Media/Basilea-to-launch-Zevtera-Mabelio-ceftobiprole-medocaril-in-Europe-through-a-commercial-services-provider/7dcfb10b-c4ef-5a82-8359-f88b1f36cb96 Mon, 21 Jul 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-to-launch-Zevtera-Mabelio-ceftobiprole-medocaril-in-Europe-through-a-commercial-services-provider/7dcfb10b-c4ef-5a82-8359-f88b1f36cb96 <![CDATA[Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections]]> http://www.basilea.com/News-and-Media/Basilea-submits-isavuconazole-European-Marketing-Authorization-Application-for-the-treatment-of-invasive-mold-infections/4829da89-e609-b167-721d-8e68389b5ba6 Thu, 17 Jul 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-submits-isavuconazole-European-Marketing-Authorization-Application-for-the-treatment-of-invasive-mold-infections/4829da89-e609-b167-721d-8e68389b5ba6 <![CDATA[Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis]]> http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-received-QIDP-designation-from-U-S-FDA-for-the-treatment-of-invasive-candidiasis/b845dff4-19aa-8671-ead5-f58974777d68 Wed, 16 Jul 2014 18:07:33 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-received-QIDP-designation-from-U-S-FDA-for-the-treatment-of-invasive-candidiasis/b845dff4-19aa-8671-ead5-f58974777d68 <![CDATA[Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections]]> http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-receives-orphan-drug-designations-in-Europe-for-the-treatment-of-invasive-mold-infections/11f1a7ab-80f8-52db-39a7-c443b9379d8a Mon, 14 Jul 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-receives-orphan-drug-designations-in-Europe-for-the-treatment-of-invasive-mold-infections/11f1a7ab-80f8-52db-39a7-c443b9379d8a <![CDATA[Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis]]> http://www.basilea.com/News-and-Media/Basileas-partner-Astellas-submits-isavuconazole-U-S-NDA-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis/150fe9ff-7b25-a61a-1bc4-69028145676e Wed, 09 Jul 2014 18:11:23 +0200 http://www.basilea.com/News-and-Media/Basileas-partner-Astellas-submits-isavuconazole-U-S-NDA-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis/150fe9ff-7b25-a61a-1bc4-69028145676e